SMN2 and proximal spinal muscular atrophy: When administered to Taiwanese Type III SMA (Smn−/−; SMN2+/+) mice, ASO-induced SMN2 splicing changes were still detectable after six months [199], suggesting that the long half-life of the drug permits several months between treatments for SMA patients [200].